Drug Trial Radar · NCT00404248
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
Last checked: Nov 19, 2026Latest source record: Mar 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Jan 2007
Primary completion
Jun 2009
Study completion Feb 2012
Sponsor
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Nov 28, 2006
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy, such as tetra-O-methyl nordihydroguaiaretic acid (EM-1421), work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I/II trial is studying the side effects and best dose of EM-1421 and to see how well it works in treating patients with recurrent high-grade glioma.
Conditions
- Brain and Central Nervous System Tumors
Interventions
terameprocolDrug
terameprocol will be given IV 5 consecutive days every 28 days. Starting dose 750mg/day. Cohorts of 3pts. A Dose Limiting Toxicity (DLT) target rate of Less than or equal to 33%. Dose levels: 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, 9300 mg.
pharmacological studyOther
All pts on both arms will have pks, blood collections. 5ml of blood will be drawn on Cycle 1 day 1, Cycle 1 Day 5, Cycle 2 day 1 and Cycle 2 day 5. A total of 10 samples will be drawn at each of these time points. 1hr pre-infusion, 15 min, 1hr, 1.15, 1.5, 2, 3,4,6 and 24hr post infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (Phase I)Time frame: first 30 days of treatment
- Maximum Tolerated Dose (Phase I) - Dose Limiting Toxicity (DLT)Time frame: First 30 days
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
UAB Comprehensive Cancer Center
Birmingham, Alabama
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
Tampa, Florida
Winship Cancer Institute of Emory University
Atlanta, Georgia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Josephine Ford Cancer Center at Henry Ford Hospital
Detroit, Michigan
Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.